The estimation of PSA kinetics, such as PSADT, is notĭifficult however, finding an important enough reason to wait for Indicated that these may provide valuable information for diagnosisĪnd staging. Previous studies on PSA kinetics, such as the PSAĭoubling time (PSADT), PSA slope, and PSA velocity ( 2– 4), have Pathological stage and PSA non-recurrence rates, novel alternative Nomogram provides reasonably accurate predictions of the Therefore, although PSA incorporation into a Wide, the PSA level alone cannot be relied upon to determine the PSA level, but considering that the range of the PSA level is so Influenced by benign prostatic hyperplasia, with poor specificityįurthermore, the pathological stage advances with an increase in Although a decision to perform prostateīiopsy is routinely based on PSA levels, the PSA level is easily (PSA), a larger number of prostate cancers in the early phase haveīeen successfully detected. With the advent of serum prostate-specific antigen A longer postoperative PSADT may facilitate the observation of patients with PSA recurrence without immediate secondary treatments. These results suggest that patients with longer preoperative PSADTs appeared to have a favorable pathological result and a higher PSA non-recurrence rate compared with those with shorter preoperative PSADTs. Pathologically, 7 of 8 patients with a post-PSADT of >24 months had a cancer confined to the prostate compared with 14 of 43 patients with a post-PSADT of <24 months.

Postoperative PSADT was measured in 51 of 111 patients with PSA failure following surgery. In total, 16 out of 20 patients with a preoperative PSADT of >24 months had a cancer confined to the prostate compared with 105 of 184 patients with a PSADT of 24 months was significantly better compared with those with a preoperative PSADT of 24 months and stable PSADT were associated with PSA recurrence following surgery, based on multivariate analysis. Preoperative PSADT was measured in 204 of the 488 patients. Preoperative and postoperative PSADT were retrospectively correlated with pathological and clinical outcomes. In total, 488 patients with T1c-3N0M0 prostate cancer who underwent radical prostatectomy were included. Therefore, the aim of the present study was to assess the clinical significance of prostate-specific antigen doubling time (PSADT) prior to and following radical prostatectomy. Although decisions to perform prostate biopsies are routinely based on PSA levels, the PSA level is easily influenced by benign prostatic hyperplasia, with poor specificity.

With the advent of serum prostate-specific antigen (PSA), a larger number of prostate cancers in the early phase have been successfully detected.

Psa doubling time survival rate